Alkem Laboratories reported a rise in third-quarter profit, supported by steady domestic formulations growth and improving operating efficiencies. In a parallel strategic move, the company announced the acquisition of a stake in Occlutech, a global medical device manufacturer, marking a significant step toward diversification beyond pharmaceuticals. The earnings uptick reflects disciplined cost management and resilient demand in key therapeutic segments. Meanwhile, the investment in Occlutech underscores Alkem’s intent to deepen its footprint in the high-value medtech space.